InvestorsHub Logo
Followers 30
Posts 3110
Boards Moderated 0
Alias Born 04/11/2010

Re: None

Friday, 01/31/2020 7:18:06 PM

Friday, January 31, 2020 7:18:06 PM

Post# of 31
This looks like the news you guys have been looking for. Congratulations. I got a proverbial boatload of this in after hours trading after the PR today. This may have as much potential as my other stock. Well not really ;)
Who would the most likely buy out offers come from?
This is going to be big.

———————————-
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy

Source: Business Wire
More than 1.6 Million Children and Teens in the U.S. are Allergic to Peanutsi,ii

Company to Host Conference Call Today at 5:30 p.m. ET

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA is the first approved treatment for patients with peanut allergy. It is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 4 through 17 years. Up-dosing and maintenance may be continued in patients 4 years of age and older. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. PALFORZIA is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200131005593/en/